The present invention relates to a transdermal drug delivery device comprising:a transdermal adhesive composition comprising:an adhesive comprising a washed polymerization reaction product of at least two ethylenically unsaturated monomers； andat least one pharmaceutically active compound which is susceptible to oxidative degradation； wherein the at least two ethylenically unsaturated monomers, if present in the adhesive as unreacted monomers, are present at a level of less than 200 ppm of total unreacted monomer, based upon the total weight of the adhesive；a backing sheet coated with the transdermal adhesive composition, wherein the transdermal adhesive composition coating covers at least a portion of a major surface of the backing sheet wherein any free radical initiator, if present in the adhesive, is present at a level of less than 20 ppm, based upon the total weight of the adhesive； andwherein less than 0.1% of antioxidant is present in the transdermal adhesive composition.少なくとも２種のエチレン性不飽和モノマーの洗浄された重合反応生成物を含む接着剤と、酸化的分解反応を受けやすい少なくとも１種の薬学的活性化合物と、を含み、少なくとも２種のエチレン性不飽和モノマーは、接着剤中に未反応モノマーとして存在する場合には、接着剤の総重量に基づいて、全未反応モノマーの２００ｐｐｍ未満の濃度で存在する、安定経皮接着剤組成物、該組成物の調製方法、該組成物を使用する経皮的薬物送達デバイス、該デバイスの製造方法、及び薬学的活性化合物の送達方法、が提供される。
